-
Founded in:
2008-08-20 -
Country:
China -
Address:
Building 3, No. 6, Rongjing East Street, Beijing Economic and Technological Development Zone, Beijing -
Tax NO.:
911103026787533566 -
Registered Funds:
170.944422 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ganciclovir |
This product is an analog of 2-deoxyguanine nucleotides that can inhibit the replication of herpes viruses. Its triphosphate form inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and incorporating into the DNA of viruses and host cells, leading to the termination of viral DNA extension. This product is effective against infections caused by cytomegalovirus (CMV) and herpes simplex virus (HSV).
More
This product is an analog of 2-deoxyguanine nucleotides that can inhibit the replication of herpes viruses. Its triphosphate form inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and incorporating into the DNA of viruses and host cells, leading to the termination of viral DNA extension. This product is effective against infections caused by cytomegalovirus (CMV) and herpes simplex virus (HSV). |
82410-32-0 | 36 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Naloxone hydrochloride dihydrate |
1. Completely or partially correct the central inhibitory effects of opioids, such as respiratory depression, sedation and hypotension. 2. It has a wake-promoting effect on animals with acute ethanol intoxication. 3. It is a pure opioid receptor antagonist and does not have the excitatory or morphine-like effects of other opioid receptor antagonists; it does not cause respiratory depression, psychotomimetic reactions or miotic reactions. 4. No drug tolerance, nor physiological or psychological dependence, has been observed. 5. Although the mechanism of action is not fully understood, there is sufficient evidence to show that it antagonizes the effects of opioids by competing for the same receptor sites.
More
1. Completely or partially correct the central inhibitory effects of opioids, such as respiratory depression, sedation and hypotension. 2. It has a wake-promoting effect on animals with acute ethanol intoxication. 3. It is a pure opioid receptor antagonist and does not have the excitatory or morphine-like effects of other opioid receptor antagonists; it does not cause respiratory depression, psychotomimetic reactions or miotic reactions. 4. No drug tolerance, nor physiological or psychological dependence, has been observed. 5. Although the mechanism of action is not fully understood, there is sufficient evidence to show that it antagonizes the effects of opioids by competing for the same receptor sites. |
51481-60-8 | 12 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Sodium sulphonate |
Opioid receptor specific antagonist, small dose (0.4-0.8 mg) intramuscular or intravenous injection can quickly reverse the effect of morphine, intravenous injection for 1-3 minutes can eliminate respiratory depression and increase respiratory rate. It has a wake-up effect on animals with acute alcohol poisoning.
More
Opioid receptor specific antagonist, small dose (0.4-0.8 mg) intramuscular or intravenous injection can quickly reverse the effect of morphine, intravenous injection for 1-3 minutes can eliminate respiratory depression and increase respiratory rate. It has a wake-up effect on animals with acute alcohol poisoning. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Naloxone hydrochloride |
1. Completely or partially correct the central inhibitory effects of opioids, such as respiratory depression, sedation and hypotension. 2. It has a wake-promoting effect on animals with acute ethanol intoxication. 3. It is a pure opioid receptor antagonist and does not have the "excitatory" or morphine-like effects of other opioid receptor antagonists; it does not cause respiratory depression, psychotomimic reactions or miotic reactions. 4. No drug tolerance, nor physiological or psychological dependence, has been observed. 5. Although the mechanism of action is still unclear, there is sufficient evidence to show that it antagonizes the effects of opioids by competing for the same receptor sites.
More
1. Completely or partially correct the central inhibitory effects of opioids, such as respiratory depression, sedation and hypotension. 2. It has a wake-promoting effect on animals with acute ethanol intoxication. 3. It is a pure opioid receptor antagonist and does not have the "excitatory" or morphine-like effects of other opioid receptor antagonists; it does not cause respiratory depression, psychotomimic reactions or miotic reactions. 4. No drug tolerance, nor physiological or psychological dependence, has been observed. 5. Although the mechanism of action is still unclear, there is sufficient evidence to show that it antagonizes the effects of opioids by competing for the same receptor sites. |
357-08-4 | 32 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Recombinant Human Interferon α2b |
It has broad-spectrum antiviral, anti-tumor, cell proliferation inhibition and immune function enhancement effects. Interferon binds to cell surface receptors to induce cells to produce a variety of antiviral proteins, inhibit virus reproduction in cells, and improve immune function, including enhancing the phagocytic function of macrophages, enhancing the cytotoxicity of lymphocytes to target cells and the function of natural killer cells.
More
It has broad-spectrum antiviral, anti-tumor, cell proliferation inhibition and immune function enhancement effects. Interferon binds to cell surface receptors to induce cells to produce a variety of antiviral proteins, inhibit virus reproduction in cells, and improve immune function, including enhancing the phagocytic function of macrophages, enhancing the cytotoxicity of lymphocytes to target cells and the function of natural killer cells. |
0 |